Patents Represented by Attorney Biotactica, LLC
  • Patent number: 7273756
    Abstract: The present invention provides a method that maintains chondrocyte phenotype during serial expansion by culturing a population of chondrocytes in a defined serum-free culture medium containing cytokines and on a substrate that is modified by covalent attachment of hyaluronic acid. The underlying principle is to maintain native chondrocyte phenotype by growing the dissociated chondrocytes on a substrate modified by covalent attachment of hyaluronic acid to retain native chondrocyte morphology and function. Chondrocyte expanded in this manner can be used in various medical applications to repair cartilaginous tissues that have been injured by trauma or disease. This substratum provides a microenvironment that more closely mimics that of native articular cartilage, thereby promoting chondrogenesis in a predictable manner.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: September 25, 2007
    Assignee: ISTO Technologies, Inc.
    Inventors: Huston Davis Adkisson, Curt L. Milliman
  • Patent number: 7238525
    Abstract: The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the translocation of Bcr-Abl to the nucleus to activate the apoptotic pathway in cancer cells.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 3, 2007
    Assignee: The Regents of the University of California
    Inventors: Jean Y. J. Wang, Paolo Vigneri